Online inquiry

IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2037MR)

This product GTTS-WQ2037MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2037MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1458MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ3030MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ6902MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ9266MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ1896MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ10159MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ13162MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ9349MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW